| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Deepak Srivastava is Director at TNYA. Deepak Srivastava's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $134K at current prices.
Net of sales, the TNYA filings show accumulation of 230,769 shares.
Deepak Srivastava has 6 Form 4 filings on record from June 2022 to May 2026, all as Director at Tenaya Therapeutics (TNYA), 2022–2026.
The 6 reported transactions were 5 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $600K and no sales.
The only open-market purchase was 230,769 shares of TNYA at an average $2.60 on November 21, 2022, about $600K. Twelve months later TNYA was down 22%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2022 | TNYA Tenaya Therapeutics, Inc. | Director | Buy | 230,769 | $2.60 | $599,999.40 | +162.9% | +36.9% | -22.3% |